Testosterone side effects, fertility and blood pressure explained, with current FDA context and the limits of replacement therapy research.
On this page
Health effects
Testosterone can cause acne, fluid retention, breast tissue growth, reduced sperm production, testicular shrinkage, high hematocrit (the proportion of blood occupied by red blood cells), blood pressure changes, worsening sleep apnea, mood effects, and other harms. Risk depends on the indication, exposure level, formulation, duration, age, health history, and other substances. Prescribed replacement for confirmed hypogonadism (deficient testosterone production) and nonmedical use at high doses are not the same exposure.
When to get help
Call local emergency services for chest pain, severe breathlessness, collapse, sudden weakness or speech difficulty, or immediate danger from suicidal thoughts. Yellow skin or eyes, persistent vomiting, new swelling or worsening symptoms need prompt medical assessment. These signs do not identify the cause by themselves.
What changed in testosterone safety information
In February 2025, the FDA requested removal of the boxed warning about increased cardiovascular outcomes following its review of TRAVERSE, while adding or strengthening blood pressure warnings. In June 2026, it requested further changes to age related limitation language and prostate safety information. Those regulatory updates concern prescribed testosterone. They do not test bodybuilding doses, mixed steroid use or unregulated products. For an individual prescription, the current local product information and clinician’s assessment remain relevant. [4]
Medical therapy and nonmedical use need separate evidence
Prescribed replacement aims to treat an assessed testosterone deficiency, with benefits and adverse effects reviewed over time. Nonmedical use often involves a different exposure and other substances. Evidence must be matched to the population and formulation studied before it is used to discuss safety.
A large 2023 cardiovascular trial studied transdermal testosterone in middle-aged and older men with hypogonadism and existing or high cardiovascular risk. Major cardiovascular events were not higher than placebo under that trial’s conditions, while atrial fibrillation, acute kidney injury, and pulmonary embolism occurred more often in the testosterone group. The result does not cover every formulation, population, exposure level, or nonmedical pattern. [2]
Formulation and exposure pattern
Injected, transdermal, nasal, buccal, and oral testosterone products do not create identical concentration patterns. A safety finding for one licensed formulation should not be copied to another without checking its evidence and label. Product quality also changes the question: a licensed prescription has controlled ingredients, while an unregulated vial or capsule may not match its claim.
Risk can change as exposure rises, but there is no single point at which every adverse effect begins. Individual health factors and concurrent drugs affect risk. A dose that is prescribed for one patient is not a safe reference for someone else. [1]
Fertility and natural hormone suppression
External testosterone suppresses luteinizing hormone and follicle stimulating hormone, reducing the signals needed for testicular testosterone production and sperm formation. Men may develop lower sperm counts, infertility, smaller testes, or changes in libido and erectile function. A person can feel stronger or have a higher measured testosterone level while sperm production is impaired.
Recovery after exposure ends is variable. Systematic reviews report that reproductive hormones and semen measures can remain altered for months, with prolonged recovery in some people. Fertility plans should be discussed before prescribed therapy begins and promptly when nonmedical exposure has occurred. Testosterone is not a fertility treatment.
For the dedicated evidence, see anabolic steroids and male fertility and hypogonadism induced by anabolic steroids. [1]
Hematocrit, clot concerns, and blood pressure
Testosterone can raise hemoglobin and hematocrit. Clinical recommendations use follow up testing because an excessive rise in red blood cells may require a change in prescribed care. A single result needs interpretation against hydration, altitude, smoking, sleep apnea, lung disease, timing, and the laboratory’s range.
FDA reviews of blood pressure monitoring studies confirmed a rise with testosterone products across the class. This does not mean that every person has the same change. New symptoms or rising readings should be discussed with the prescriber rather than managed by adding another drug without advice.
See hematocrit and blood clot risk for the broader AAS evidence. [3]
Prostate, urinary, breast, and fluid effects
New urinary difficulty or a breast lump warrants assessment rather than an assumption about testosterone. Prostate safety language has changed as evidence has developed, including FDA label requests in 2026. A history of prostate or breast disease still belongs in the clinical discussion; neither reassurance nor a diagnosis follows from one hormone result.
Aromatization of testosterone to estradiol can contribute to breast tenderness or gynecomastia. Fluid retention may be more concerning in people with heart, kidney, or liver disease. Adding an unprescribed drug to counter breast or fluid symptoms can create new risks and interactions. [4]
Skin, hair, sleep, and mood
Acne and oily skin are common androgenic complaints. Scalp hair loss may progress in genetically susceptible people. Testosterone can worsen sleep apnea, which may also contribute to high blood pressure, daytime fatigue, and high hematocrit.
Mood responses vary. Some people report irritability, anxiety, unusually high mood, aggression, depression, or sleep disruption, especially with nonmedical exposure or withdrawal. Prior mental health conditions and other substances can affect symptoms. Suicidal thoughts, psychosis, or dangerous agitation needs urgent help. [5]
What clinicians may assess
Assessment can include the indication, formulation, timing, symptoms, fertility goals, blood pressure, sleep symptoms, cardiovascular and prostate history, other medicines, and nonprescribed substances. Depending on context, a clinician may review blood count, testosterone measurements, lipids, or other tests tied to symptoms and risk.
Testing schedules and treatment changes belong to the prescribing clinician. Normal results do not rule out every harm, and an abnormal result should not be treated without clinical guidance. Bring a complete list of products and be direct about nonmedical use. Read talking to a doctor about anabolic steroid use. [1]
Prepare for a medical appointment
Bring the product name, packaging or a photo, the dates used, when symptoms began, and a list of other medicines and supplements. Say if any product came from an uncertain source. Ask which findings need follow up and what should trigger urgent care.
Plan a conversation with a clinician. For a prescribed medicine, contact the prescriber before making treatment changes.
Sources
- Endocrine Society recommendations for testosterone therapy (2018-03-19).
- TRAVERSE cardiovascular safety trial (2023).
- FDA testosterone blood pressure and cardiovascular label update (2025-02-28).
- FDA testosterone information and June 2026 label requests (2026-06).
- Diagnosis and management of anabolic steroid use (2019).